Last updated on October 2018

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea


Brief description of study

This is a 12-week, multicenter, double-blind, randomized, two-arm, vehicle controlled study. Subjects will be randomized 1:1 to BPX-04 minocycline topical gel 1% or vehicle. This study will include approximately 176 randomized subjects with inflammatory lesions of papulopustular rosacea on the face, defined by an IGA score of 3 (moderate) or 4 (severe) at Baseline. Subjects will be healthy male or female subjects aged 18 years or older. There will be up to 20 study sites in the USA.

Detailed Study Description

This is a 12-week, multicenter, double-blind, randomized, two-arm, vehicle controlled study. Subjects will be randomized 1:1 to BPX-04 minocycline topical gel 1% or vehicle. This study will include approximately 176 randomized subjects with inflammatory lesions of papulopustular rosacea on the face, defined by an IGA score of 3 (moderate) or 4 (severe) at Baseline. Subjects will be healthy male or female subjects aged 18 years or older. There will be up to 20 study sites in the USA.

Subjects will apply approximately 1 gram of topical gel once each day for a 12 week duration. They will come to the study site at Screening, Baseline, and Weeks 4, 8, and 12 or early termination (ET) for the protocol required efficacy and safety evaluations.

At each visit, efficacy will be assessed by rosacea lesion counts, IGA, PGI-S, PGI-I, CGI-S, CGI-I, RosaQoL, Erythema Assessment Scale, Telangiectasia Assessment Scale and subject satisfaction questionnaire.

Safety will be assessed with vital signs, physical examination, laboratory tests such as clinical hematology and chemistries, investigators' and subjects' assessments of cutaneous tolerability, incidence of minocycline-induced skin hyperpigmentation, incidence of visual disturbances and/or headaches suggestive of pseudotumor cerebri, and incidence of TEAEs. Blood samples will be collected to evaluate the level of minocycline in plasma at Baseline and Week 12/ET.

Clinical Study Identifier: NCT03667222

Contact Investigators or Research Sites near you

Start Over

AnnaMarie Daniels

Study Center
Anaheim Hills, CA United States
  Connect »

AnnaMarie Daniels

Study Center
Miami, FL United States
  Connect »

AnnaMarie Daniels

Study Center
Miramar, FL United States
  Connect »

AnnaMarie Daniels

Study Center
New Orleans, LA United States
  Connect »

AnnaMarie Daniels

Study Center
Needham, MA United States
  Connect »

AnnaMarie Daniels

Study Center
Saint Joseph, MO United States
  Connect »

AnnaMarie Daniels

Study Center
High Point, NC United States
  Connect »

AnnaMarie Daniels

Study Center
Philadelphia, PA United States
  Connect »